Orakl Oncology is a technology-first biotechnology company developing a simulation platform that integrates tumour models with clinical and omics data to replicate drug responses. Its platform enables pharmaceutical and research partners to derive insights from experimental data, accelerating oncology drug development. Founded in 2023, Orakl collaborates across the oncology ecosystem to advance precision medicine.